OK Biotech Co., Ltd. (4155.TW)
TWD 20.9
(-0.71%)
TWD 20.9
(-0.71%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 9.94 Million TWD | -94.6% |
| 2022 | 184.22 Million TWD | 35.58% |
| 2021 | 135.88 Million TWD | 151.98% |
| 2020 | -261.4 Million TWD | -229.53% |
| 2019 | 201.81 Million TWD | 171.46% |
| 2018 | 74.34 Million TWD | 206.55% |
| 2017 | -69.77 Million TWD | -155.09% |
| 2016 | 126.66 Million TWD | -40.62% |
| 2015 | 213.29 Million TWD | -46.16% |
| 2014 | 396.17 Million TWD | -12.58% |
| 2013 | 453.18 Million TWD | 503.81% |
| 2012 | -112.22 Million TWD | -96.18% |
| 2011 | -57.2 Million TWD | -481.08% |
| 2010 | -9.84 Million TWD | -155.52% |
| 2009 | 17.73 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 51.08 Million TWD | 413.85% |
| 2024 Q2 | 179.66 Million TWD | 251.68% |
| 2023 Q4 | 9.94 Million TWD | 108.5% |
| 2023 Q2 | 137.21 Million TWD | -32.94% |
| 2023 Q3 | -116.98 Million TWD | -185.26% |
| 2023 FY | 9.94 Million TWD | -94.6% |
| 2023 Q1 | 204.62 Million TWD | 11.07% |
| 2022 Q4 | 184.22 Million TWD | -56.39% |
| 2022 FY | 184.22 Million TWD | 35.58% |
| 2022 Q1 | 202.56 Million TWD | 49.07% |
| 2022 Q2 | 190.59 Million TWD | -5.91% |
| 2022 Q3 | 422.42 Million TWD | 121.64% |
| 2021 Q3 | 136.7 Million TWD | 233.42% |
| 2021 Q4 | 135.88 Million TWD | -0.6% |
| 2021 FY | 135.88 Million TWD | 151.98% |
| 2021 Q1 | -150.92 Million TWD | 42.26% |
| 2021 Q2 | -102.46 Million TWD | 32.11% |
| 2020 Q3 | -71.21 Million TWD | -127.26% |
| 2020 Q2 | 261.19 Million TWD | 16.95% |
| 2020 Q4 | -261.4 Million TWD | -267.09% |
| 2020 Q1 | 223.33 Million TWD | 10.66% |
| 2020 FY | -261.4 Million TWD | -229.53% |
| 2019 Q3 | 291.49 Million TWD | 64.06% |
| 2019 Q4 | 201.81 Million TWD | -30.77% |
| 2019 Q1 | 40.2 Million TWD | -45.92% |
| 2019 Q2 | 177.67 Million TWD | 341.94% |
| 2019 FY | 201.81 Million TWD | 171.46% |
| 2018 Q2 | -133.61 Million TWD | -19.85% |
| 2018 FY | 74.34 Million TWD | 206.55% |
| 2018 Q1 | -111.48 Million TWD | -59.77% |
| 2018 Q4 | 74.34 Million TWD | -28.82% |
| 2018 Q3 | 104.45 Million TWD | 178.17% |
| 2017 FY | -69.77 Million TWD | -155.09% |
| 2017 Q4 | -69.77 Million TWD | -137.0% |
| 2017 Q3 | 188.6 Million TWD | 27.85% |
| 2017 Q2 | 147.51 Million TWD | 10.65% |
| 2017 Q1 | 133.31 Million TWD | 5.25% |
| 2016 Q4 | 126.66 Million TWD | 0.0% |
| 2016 Q1 | 75.76 Million TWD | -64.48% |
| 2016 FY | 126.66 Million TWD | -40.62% |
| 2016 Q2 | 135.69 Million TWD | 79.1% |
| 2015 Q1 | 261.38 Million TWD | -34.02% |
| 2015 Q3 | 230.34 Million TWD | -6.06% |
| 2015 Q2 | 245.2 Million TWD | -6.19% |
| 2015 FY | 213.29 Million TWD | -46.16% |
| 2015 Q4 | 213.29 Million TWD | -7.4% |
| 2014 Q1 | 479.69 Million TWD | 5.85% |
| 2014 FY | 396.17 Million TWD | -12.58% |
| 2014 Q4 | 396.17 Million TWD | -3.81% |
| 2014 Q3 | 411.88 Million TWD | -11.51% |
| 2014 Q2 | 465.47 Million TWD | -2.96% |
| 2013 Q1 | 362.14 Million TWD | 422.69% |
| 2013 Q2 | 371.24 Million TWD | 2.51% |
| 2013 FY | 453.18 Million TWD | 503.81% |
| 2013 Q4 | 453.18 Million TWD | -1.29% |
| 2013 Q3 | 459.11 Million TWD | 23.67% |
| 2012 Q4 | -112.22 Million TWD | 48.88% |
| 2012 Q2 | -53.31 Million TWD | 0.0% |
| 2012 Q3 | -219.54 Million TWD | -311.8% |
| 2012 FY | -112.22 Million TWD | -96.18% |
| 2011 FY | -57.2 Million TWD | -481.08% |
| 2011 Q2 | -24.44 Million TWD | 0.0% |
| 2011 Q4 | -57.2 Million TWD | 0.0% |
| 2010 FY | -9.84 Million TWD | -155.52% |
| 2010 Q4 | -9.84 Million TWD | 0.0% |
| 2009 FY | 17.73 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Excelsior Medical Co., Ltd. | -1.17 Billion TWD | 100.849% |
| Apex Medical Corp. | -283.82 Million TWD | 103.503% |
| Applied BioCode Corporation | -378.76 Million TWD | 102.625% |